Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Exosome release and low pH belong to a framework of resistance of human melanoma cells to cisplatin.

Federici C, Petrucci F, Caimi S, Cesolini A, Logozzi M, Borghi M, D'Ilio S, Lugini L, Violante N, Azzarito T, Majorani C, Brambilla D, Fais S.

PLoS One. 2014 Feb 6;9(2):e88193. doi: 10.1371/journal.pone.0088193. eCollection 2014.

2.

Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs.

Luciani F, Spada M, De Milito A, Molinari A, Rivoltini L, Montinaro A, Marra M, Lugini L, Logozzi M, Lozupone F, Federici C, Iessi E, Parmiani G, Arancia G, Belardelli F, Fais S.

J Natl Cancer Inst. 2004 Nov 17;96(22):1702-13.

PMID:
15547183
3.

Microenvironmental pH is a key factor for exosome traffic in tumor cells.

Parolini I, Federici C, Raggi C, Lugini L, Palleschi S, De Milito A, Coscia C, Iessi E, Logozzi M, Molinari A, Colone M, Tatti M, Sargiacomo M, Fais S.

J Biol Chem. 2009 Dec 4;284(49):34211-22. doi: 10.1074/jbc.M109.041152. Epub 2009 Sep 30.

4.

pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity.

De Milito A, Canese R, Marino ML, Borghi M, Iero M, Villa A, Venturi G, Lozupone F, Iessi E, Logozzi M, Della Mina P, Santinami M, Rodolfo M, Podo F, Rivoltini L, Fais S.

Int J Cancer. 2010 Jul 1;127(1):207-19. doi: 10.1002/ijc.25009.

5.

Lansoprazole induces sensitivity to suboptimal doses of paclitaxel in human melanoma.

Azzarito T, Venturi G, Cesolini A, Fais S.

Cancer Lett. 2015 Jan 28;356(2 Pt B):697-703. doi: 10.1016/j.canlet.2014.10.017. Epub 2014 Oct 23.

PMID:
25449440
6.

Proton pump inhibitors may reduce tumour resistance.

De Milito A, Fais S.

Expert Opin Pharmacother. 2005 Jun;6(7):1049-54. Review.

PMID:
15957961
7.

Tumor acidity, chemoresistance and proton pump inhibitors.

De Milito A, Fais S.

Future Oncol. 2005 Dec;1(6):779-86. Review.

PMID:
16556057
8.

Proton pump inhibitors (PPIs) impact on tumour cell survival, metastatic potential and chemotherapy resistance, and affect expression of resistance-relevant miRNAs in esophageal cancer.

Lindner K, Borchardt C, Schöpp M, Bürgers A, Stock C, Hussey DJ, Haier J, Hummel R.

J Exp Clin Cancer Res. 2014 Sep 1;33:73. doi: 10.1186/s13046-014-0073-x.

9.

Proton pump inhibitor-induced tumour cell death by inhibition of a detoxification mechanism.

Fais S.

J Intern Med. 2010 May;267(5):515-25. doi: 10.1111/j.1365-2796.2010.02225.x. Review.

10.

Multidrug resistant P-glycoprotein positive L1210/VCR cells are also cross-resistant to cisplatin via a mechanism distinct from P-glycoprotein-mediated drug efflux activity.

Gibalová L, Sedlák J, Labudová M, Barancík M, Reháková A, Breier A, Sulová Z.

Gen Physiol Biophys. 2009 Dec;28(4):391-403.

PMID:
20097962
11.

Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species.

De Milito A, Iessi E, Logozzi M, Lozupone F, Spada M, Marino ML, Federici C, Perdicchio M, Matarrese P, Lugini L, Nilsson A, Fais S.

Cancer Res. 2007 Jun 1;67(11):5408-17.

12.

Effects and mechanisms of proton pump inhibitors as a novel chemosensitizer on human gastric adenocarcinoma (SGC7901) cells.

Chen M, Zou X, Luo H, Cao J, Zhang X, Zhang B, Liu W.

Cell Biol Int. 2009 Sep;33(9):1008-19. doi: 10.1016/j.cellbi.2009.05.004. Epub 2009 Jun 6.

PMID:
19501661
13.

P-glycoprotein depresses cisplatin sensitivity in L1210 cells by inhibiting cisplatin-induced caspase-3 activation.

Gibalová L, Sereš M, Rusnák A, Ditte P, Labudová M, Uhrík B, Pastorek J, Sedlák J, Breier A, Sulová Z.

Toxicol In Vitro. 2012 Apr;26(3):435-44. doi: 10.1016/j.tiv.2012.01.014. Epub 2012 Jan 17.

PMID:
22269388
14.

Interaction between the anticancer drug Cisplatin and the copper chaperone Atox1 in human melanoma cells.

Palm-Espling ME, Lundin C, Björn E, Naredi P, Wittung-Stafshede P.

Protein Pept Lett. 2014;21(1):63-8.

PMID:
23988033
15.

Manipulating tumor acidification as a cancer treatment strategy.

McCarty MF, Whitaker J.

Altern Med Rev. 2010 Sep;15(3):264-72. Review.

16.

Regulation of exosome release from mammary epithelial and breast cancer cells - a new regulatory pathway.

Riches A, Campbell E, Borger E, Powis S.

Eur J Cancer. 2014 Mar;50(5):1025-34. doi: 10.1016/j.ejca.2013.12.019. Epub 2014 Jan 22.

PMID:
24462375
17.

Differential response of normal, dedifferentiated and transformed thyroid cell lines to cisplatin treatment.

Muscella A, Urso L, Calabriso N, Ciccarese A, Migoni D, Fanizzi FP, Di Jeso B, Storelli C, Marsigliante S.

Biochem Pharmacol. 2005 Dec 19;71(1-2):50-60. Epub 2005 Nov 16.

PMID:
16297374
18.

Low pH increases the yield of exosome isolation.

Ban JJ, Lee M, Im W, Kim M.

Biochem Biophys Res Commun. 2015 May 22;461(1):76-9. doi: 10.1016/j.bbrc.2015.03.172. Epub 2015 Apr 4.

PMID:
25849885
19.

Reversal of multidrug resistance by cisplatin-loaded magnetic Fe3O4 nanoparticles in A549/DDP lung cancer cells in vitro and in vivo.

Li K, Chen B, Xu L, Feng J, Xia G, Cheng J, Wang J, Gao F, Wang X.

Int J Nanomedicine. 2013;8:1867-77. doi: 10.2147/IJN.S43752. Epub 2013 May 9.

20.

Cell proliferation, apoptosis and mitochondrial damage in rat B50 neuronal cells after cisplatin treatment.

Bottone MG, Soldani C, Veneroni P, Avella D, Pisu M, Bernocchi G.

Cell Prolif. 2008 Jun;41(3):506-20. doi: 10.1111/j.1365-2184.2008.00530.x. Epub 2008 Apr 7.

PMID:
18397337

Supplemental Content

Support Center